| |
|
|
|
CytomX Therapeutics Inc.  
|
|
9.27 0.02 (0%) |
09-17 16:00 |
|
Open: |
9.13 |
Pre close: |
9.25 |
Target:
|
11.63 
|
|
High: |
9.4 |
Low: |
8.88 |
Resistance:
|
9.96
11.63
|
|
Volume: |
161,252 |
Market Cap: |
421M |
Support:
|
8.79
8.07
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
9.43
|
MACD |
MACD(12,26):
|
-0.14  |
|
MA(20): |
9.02 |
Signal(12,26,9): |
-0.26 |
|
MA(100): |
10.27 |
Stochastic Oscillator |
%K(14,3):
|
58.91 |
|
MA(250): |
12.80 |
%D(3): |
67.55 |
|
Average Volume(K) |
3-Month: |
29129
|
52-Week |
High:
|
19.75 |
|
10-Days: |
23302 |
Low: |
8.07 |
|
RSI |
RSI(14):
|
49.22 |
Change(%): |
-50.8 |
|
Financials, Statistics and Valuation |
|
EPS |
-2.200 |
Return on Equity (ttm) |
-138.5 |
Shares Out. (M) |
45.41 |
|
EPS Est. Current Year |
-1.490 |
Return on Assets (ttm) |
-15.5 |
Shares Float (M) |
41.20 |
|
EPS Est. Next Year |
-1.410 |
PEG Ratio |
5.28 |
% Held by Insiders |
2.50 |
|
EPS Est. Next Quarter |
-0.410 |
Qtrly Rev. Growth |
-57.8 |
% Held by Institutions |
86.29 |
|
Forward EPS |
-2.081 |
Gross Profit (p.s.) |
1.310 |
Shares Short (K) |
1830 |
|
Book Value (p.s.) |
2.240 |
EBITDA (p.s.) |
-2.080 |
P/E |
-4.22 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
4.14 |
|
Profit Margin |
-158.05 |
Operating Cash Flow
(M) |
-121.97 |
P/S |
303168928.00 |
|
Operating Margin |
-154.91 |
Levered Free Cash Flow
(M) |
-36.00 |
P/CF |
-3.45 |
|
|
|
|
|
|
